Previous 10 | Next 10 |
2024-06-07 15:00:58 ET More on the markets Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) SPY: 2 Options To Balance Out A Highly Concentrated Index Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity Citi – ...
2024-06-07 10:32:06 ET Summary Halozyme Therapeutics, Inc. raised both its full year 2024 financial guidance and 5-year financial outlook on Thursday, sending the stock 12% higher. Halozyme Therapeutics continues to execute well, is buying back a significant amount of its own stoc...
2024-06-06 22:31:45 ET More on Geron Geron Corporation: A High-Risk Deal With A Good Chance Of Success Geron Corporation (GERN) Q1 2024 Earnings Call Transcript Geron: FDA PDUFA Review With Continued Imetelstat Advancement Geron GAAP EPS of -$0.09 beats by $0...
2024-06-06 12:05:40 ET More on Replimune Group Replimune: Continuing To Justify The Bear Thesis (For Now) Seeking Alpha’s Quant Rating on Replimune Group Historical earnings data for Replimune Group Financial information for Replimune Group R...
2024-06-06 10:47:18 ET More on 2seventy bio 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...
2024-06-06 09:00:00 ET Summary The Dividend Harvesting Portfolio generated over $100 of dividend income in May, with a return on invested capital of 14.14%. The portfolio's diversification helped stabilize market conditions, with a 1.45% growth in profitability despite market decl...
2024-06-05 09:15:55 ET More on Bristol-Myers Squibb Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Gener...
2024-06-04 11:20:58 ET Summary Schrödinger is a hybrid biopharma company specializing in physics-based computational chemistry and traditional drug development. The company aims to utilize computational methods to create better drug candidates and improve strategic decision-m...
2024-06-04 10:26:59 ET More on Bristol-Myers Squibb Company Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be...
2024-06-04 09:00:00 ET Summary Bristol-Myers Squibb has experienced significant declines in its stock price, but I believe it has potential for future growth. The risks of investing in BMY include underperformance compared to the market and potential setbacks in its drug pipeline....
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...